In a 2026 Alberta study of 1,070 adults leaving psychiatric hospital care, 40% returned to an emergency department for mental health reasons within a year. The strongest warning signs were social rather than clinical: a recent emergency visit before admission (3.72 times the odds), unstable housing (2.60 times), and unemployment (1.57 times).1 Research Highlights Recent …
A 2026 German-Austrian cohort analysis found that people with schizophrenia who were taking quetiapine scored modestly higher on demanding working-memory tests than sex- and age-matched patients who were not, with the largest gap at doses of 300 mg a day or less.1 Because patients were not randomized to quetiapine, this is an association; the advantage …
A 2026 study of 1,250 Florida youth in juvenile-justice programs who had attempted suicide found that 557 (45%) denied serious suicidal thoughts or a plan. Anger or irritability was more common among them than among youth reporting suicidal thoughts (40% vs. 30%).1 An earlier 427-youth sample found a 40% denial rate.2 Screening that starts with …
A 2026 umbrella review of 16 systematic reviews covering 371 trials found strong medication evidence for tobacco and opioid use disorders, modest benefits for alcohol use disorder, and no approved drugs for stimulant or cannabis use disorders.1 Varenicline more than doubled smoking quit rates vs. placebo, methadone kept people in opioid treatment longer than buprenorphine, …
At entry to US specialty clinics, 34% of 2,951 young people with first-episode psychosis reported suicidal thoughts and 7% had attempted suicide in the previous 6 months. A 2026 Early Psychosis Intervention Network (EPINET) analysis found odds fell 76% for thoughts and 85% for attempts over 2 years of care.1 With no comparison group, the …
A 2026 analysis of 41 randomized studies involving 21,025 adults with schizophrenia found the largest estimated reductions in hostility and aggression for clozapine (standardized mean difference, or SMD, of −0.75), paliperidone (−0.62), and olanzapine (−0.60) vs. placebo.1 Confidence in every comparison was low or very low, the top 3 were not statistically separable, and most …
A 2026 meta-analysis of 50 studies estimated that about 1 in 3 people with neurofibromatosis type 1 (NF1) have ADHD (33%), and that roughly 1 in 10 have autism (11%), seizures (11%), depression (13%), or anxiety (12%).1 Every one of those figures sits well above typical population rates, but the individual studies disagreed so widely …